OGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Organon & Co (OGN) is not a strong buy at this time for a beginner investor with a long-term strategy. The technical indicators are bearish, the financial performance shows significant declines in net income and EPS, and the analyst rating is underweight with a price target below the current price. While there are some positive catalysts in the atopic dermatitis market, they are not enough to offset the negative trends in financials and technicals. Holding or exploring other opportunities may be more prudent.
The technical indicators are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 41.523, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point of 7.531, with key resistance at 8.276 and support at 6.786.
The atopic dermatitis treatment market is projected to grow positively by 2034, with high demand for new therapies. New drugs like Rocatinlimab and Amlitelimab are expected to enhance treatment options, which could benefit the company in the long term.
Barclays initiated coverage with an underweight rating and a $7.50 price target, indicating limited upside. The company's financial performance in Q3 2025 showed a significant decline in net income (-55.43%) and EPS (-55.80%). Gross margin also dropped by 8.30%. Technical indicators suggest a bearish trend, and the stock has a 70% chance of declining in the short term.
In Q3 2025, revenue increased by 1.26% YoY to $1.602 billion. However, net income dropped by 55.43% YoY to $160 million, EPS fell by 55.80% to 0.61, and gross margin decreased by 8.30% to 53.5%. These declines indicate weakening profitability.
Barclays initiated coverage with an Underweight rating and a $7.50 price target. The firm noted that the specialty pharmaceuticals industry is in a transition phase, with easing pricing headwinds and improving investor sentiment. However, the underweight rating reflects limited confidence in Organon's near-term performance.
